Ora­sis Phar­ma­ceu­ti­cals snags $30M to see its pres­by­opia treat­ment through to PhI­II

Ora­sis Phar­ma­ceu­ti­cals is one of sev­er­al biotechs de­vel­op­ing mi­otic-based eye drops as a po­ten­tial al­ter­na­tive to read­ing glass­es — one drop, and no more squint­ing at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER